Clinical Trial Update: Sintilimab and Lenalidomide as a Treatment for CAEBV [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sintilimab plus lenalidomide for chronic active Epstein-Barr virus disease (CAEBV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Epstein-barr Virus Disease

Drugs mentioned

• Lenalidomide (lenalidomide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhao Wang | Conditions: CAEBV | Phase 2 | Status: UNKNOWN